Kyverna Therapeutics (KYTX) to Release Earnings on Tuesday

Key Points

• Kyverna will report Q1 2026 results before the market opens on May 12, with analysts expecting earnings of about ($0.75) per share and a conference call scheduled for May 11 at 4:00 PM ET.
• The company is a clinical‑stage biotech developing engineered regulatory T‑cell (Treg) therapies—its lead allogeneic Treg program targets ulcerative colitis—and analysts forecast roughly ($3) EPS for the current and next fiscal years.
• Shares traded around $9.12 with a market cap of about $552M and a 52‑week range of $1.92–$13.67; Wall Street shows mixed coverage but a consensus of "Moderate Buy" and an average target of $28.67 (four buys, one sell).

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) will likely be posting its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Kyverna Therapeutics to post earnings of ($0.75) per share for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its earnings results on Thursday, March 26th. The company reported ($0.80) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.80). On average, analysts expect Kyverna Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kyverna Therapeutics Price Performance

NASDAQ:KYTX traded up $0.12 during midday trading on Tuesday, hitting $9.12. The company had a trading volume of 357,783 shares, compared to its average volume of 867,113. Kyverna Therapeutics has a 52-week low of $1.92 and a 52-week high of $13.67. The stock's fifty day moving average price is $8.73 and its 200-day moving average price is $8.21. The company has a market capitalization of $552.03 million, a PE ratio of -2.50 and a beta of 2.05. The company has a quick ratio of 7.75, a current ratio of 7.75 and a debt-to-equity ratio of 0.11.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on KYTX shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Kyverna Therapeutics in a research note on Thursday, April 23rd. Finally, Wall Street Zen lowered Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 21st. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $28.67.

Institutional Trading of Kyverna Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio purchased a new stake in Kyverna Therapeutics in the third quarter worth $28,000. EntryPoint Capital LLC purchased a new position in shares of Kyverna Therapeutics in the 4th quarter worth about $94,000. Ameriprise Financial Inc. purchased a new position in shares of Kyverna Therapeutics in the 3rd quarter worth about $77,000. Qube Research & Technologies Ltd purchased a new position in Kyverna Therapeutics in the 2nd quarter worth approximately $43,000. Finally, Jefferies Financial Group Inc. purchased a new position in Kyverna Therapeutics in the 3rd quarter worth approximately $98,000. Hedge funds and other institutional investors own 18.08% of the company's stock.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.